Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: A multiple propensity score-adjusted retrospective cohort study

Drugs and Aging

Volumn 29, Issue 10, 2012, Pages 807-817

  Chatterjee, Satabdi ^a   Chen, Hua ^a   Johnson, Michael L ^a   Aparasu, Rajender R ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; OLANZAPINE; QUETIAPINE; RISPERIDONE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD VESSELS; BRAIN; COHORT STUDIES; DIBENZOTHIAZEPINES; EMERGENCY MEDICAL SERVICES; FEMALE; HOSPITALIZATION; HOUSING; HUMANS; MALE; MIDDLE AGED; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; RISK; RISPERIDONE;

EID: 84874597440     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0013-4     Document Type: Article

References (46)

1. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
2. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD003476.
3. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res. 2001;48:17-28. (Pubitemid 32241180)
4. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-43. (Pubitemid 41464695)
5. Recupero PR, Rainey SE. Managing risk when considering the use of atypical antipsychotics for elderly patients with dementia-related psychosis. J Psychiatr Pract. 2007;13(3):143-52. (Pubitemid 46809446)
6. Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu G, De Sarro G. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging. 2006;23(12):937-56. (Pubitemid 44936061)
7. Jano E, Johnson M, Chen H, Aparasu RR. Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin. 2008;24(3):709-16. (Pubitemid 351428983)
8. Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009;23(8):909-14.
9. Smith D, Beier M. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc. 2004;5(2):129-32. (Pubitemid 38380415)
10. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167(11):1269-70. (Pubitemid 35370646)
11. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;170(9):1395. (Pubitemid 38594631)
12. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134-43. (Pubitemid 36268315)
13. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19(2):91-103. (Pubitemid 40321762)
14. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968-76.
15. Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17(4):617-29. (Pubitemid 41758766)
16. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330(7489):445. (Pubitemid 40314208)
17. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161(6):1113-5. (Pubitemid 38736000)
18. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66:1090-6. (Pubitemid 41442273)
19. Layton D, Harris S, Wilton LV, Shakir SAW. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19(5):473-82. (Pubitemid 41392301)
20. Barnett M, Wehrig H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007;27:595-601. (Pubitemid 351339446)
21. Perccudani M, Barbui C, Fortino I, Tansella M, Petrovich L. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol. 2005;25:468-70. (Pubitemid 41368370)
22. Mehta S, Johnson ML, Chen H, Aparasu RR. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. J Clin Psychiatry. 2010;71(6):689-98.
23. Ray W. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20. (Pubitemid 37323253)
24. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-32. (Pubitemid 46426056)
25. Agency for Healthcare Research and Quality Center for Cost and Financing Studies. MEPS HC-052. 2000 medical conditions. June 2003. http://www.meps.ahrq. gov/mepsweb/data-stats/download-data/pufs/h52/h52doc.pdf. Accessed 2009 Apr 16.
26. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
27. Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med. 2010;29(20):2137-48.
28. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf. 2004;13(12):841-53. (Pubitemid 40003819)
29. Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005;58(6):550-9. (Pubitemid 40692720)
30. Spreeuwenberg MD, Bartak A, Croon MA, Hagenaars JA, Busschbach JJ, Andrea H, et al. The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care. 2010;48(2):166-74.
31. Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc. 1973;51(1):95-124.
32. Aparasu RR, Jano E, Johnson ML, Chen H. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am J Geriatr Pharmacother. 2008;6(4):198-204.
33. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika. 2000;87:706-10.
34. McFadden D, Train K, Tye W. An application of diagnostic tests for the independence from irrelevant alternatives property of the multinomial logit model. Transp Res Rec. 1976;637:39-45.
35. Furie KL, Kelly PJ. Handbook of stroke prevention in clinical practice. Totowa: Humana Press; 2004.
36. Gottlieb S. Warnings issued over COX 2 inhibitors in US and UK. BMJ. 2005;330(9):4.
37. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897-902. (Pubitemid 24179151)
38. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1999;124(11):970-9.
39. Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA. 2003;289(5):537-8. (Pubitemid 37428620)
40. Greenspan A, Eerdekens M, Mahmoud R. Is there an increased risk of cerebrovascular adverse events among dementia patients treated with risperidone? In: Proceedings of the annual meeting of the International College of Geriatric Psychoneuropharmacology, San Juan, 12-14 Dec 2003.
41. Greenspan A, Eerdekens M, Mahmoud R. Is there an increased rate of cerebrovascular adverse events with risperidone in patients with dementia? [abstract]. Int J Neuropsychopharmacol. 2004;7(Suppl. 1):S205.
42. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18:63-101. (Pubitemid 28026679)
43. Hellewell JSE, Gerlach J. Opportunities and challenges presented by new generation antipsychotics. Int J Psych Clin Pract. 2000;4(Suppl 1):53-62.
44. Hellewell JSE. Quetiapine: a well-tolerated and effective atypical antipsychotic. Hosp Med. 2002;63(10):600-3.
45. Perkins DO. Antipsychotic-induced hyperprolactinemia: pathophysiology and clinical consequences. Adv Stud Med. 2004;4(10F):S982-6. (Pubitemid 40040865)
46. Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs. 2004;18(15):1119-32. (Pubitemid 40007494)